Gilead Sciences (GILD)
$62.98 0.22 (0.35%)
19:51 EST GILD Stock Quote Delayed 15 Minutes
Previous Close $62.98
Market Cap 81.89B
PE Ratio 23.95
Volume (Avg. Vol.) 13.46M
Day's Range 62.57 - 63.50
52-Week Range 60.89 - 70.50
Dividend & Yield 2.23 (3.54%)
GILD Stock Predictions, Articles, and Gilead Sciences News
- From InvestorPlace
- From the Web
These three biopharma stocks to buy should help investors maintain strength amid any potential chaos in 2019.
In a turbulent year for Gilead Sciences (NASDAQ:GILD), the company recently generated headlines that will hopefully turn things around for GILD stock. Over the weekend,....
Wall Street isn’t necessarily a cutthroat, avaricious platform as these best stocks to buy for the holiday season demonstrate.
Healthcare stocks recovered throughout 2018 but the recent correction in some big names is creating an entry point.
GILD stock should benefit as its new products, including treatments for liver cirrhosis and HIV, come to market.
Healthcare stocks face political uncertainty. However, this mix of 7 buys offers broad diversity, and it profits from the aging of America.
Looking for blockbuster potential? These five biotech stocks may have found it in treating NASH -- an untapped market of up to $35 billion.
Impatient investors are waiting for Gilead stock to break out, but that will not happen right away. As Gilead develops its pipeline, however, GILD stock will rebound.
There is no shortage of dividend stock lists out there. But what sets a top dividend stock apart isn’t simply the dividend payment. If you are going to invest in a dividend stock it should be a worthy investing proposition.
What's the next big thing in biotech? The answer is gene therapy and these five biotech stocks are leading the way.
Drug stocks have been beaten up ever since the 2015 collapse of Valeant, but many of them are now too cheap to ignore.
There’s a lot uncertainty in today’s market, but one thing is guaranteed ... The new tax reform law is about to cause an avalanche of money to rush into dividend stocks in the weeks and months ahead.
The stock charts of Wells Fargo, Philip Morris and Gilead Sciences are shaping up as this week's most compelling prospects.
Navellier RatingsPowered by Portfolio Grader